{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T21:57:48Z","timestamp":1775599068527,"version":"3.50.1"},"reference-count":56,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Radio-iodine refractory (RAI-R) differentiated thyroid cancer (DTC) is a rare disease with a poor prognosis and limited therapeutic resources. Therefore, identifying prognostic factors is essential in order to select patients who could benefit from an early start of treatment. The aim of this study is to identify positron emission tomography with 18F-fluorodeoxyglucose with integrated computed tomography (18F-FDG-PET\/CT) parameters to predict overall survival (OS) in patients with RAI-R DTC. In this single-center retrospective study, we analyze the 18F-FDG-PET\/CT parameters of 34 patients with RAI-R DTC between April 2007 and December 2019. The parameters collected are MTV, SUVmax and progression for each site of metastasis (neck, mediastinum, lungs, liver, bone) and total sites. ROC curves, Kaplan\u2013Meier survival analysis curves, univariate and multivariate Cox analyses determine prognostic factors for 1-year and 5-year OS. The parameters for mediastinum, liver and total sites are significantly associated with worse 1-year and 5-year OS by both ROC curve analysis and Kaplan\u2013Meier survival analysis. Univariate Cox analysis confirms significance of mediastinum SUVmax (HR 1.08; 95% CI [1.02\u20131.15]; p = 0.014) and total SUVmax (HR 1.06; 95% CI [1\u20131.12]; p = 0.042) for worse 1-year OS; of mediastinum SUVmax (HR 1.06; 95% CI [1.02\u20131.10]; p = 0.003), liver SUVmax (HR 1.04; 95% CI [1.01\u20131.08]; p = 0.02), liver MTV (HR 2.56; 95% CI [1.13\u20135.82]; p = 0.025), overall SUVmax (HR 1.05; 95% CI [1.02\u20131.08]; p = 0.001) and total MTV (HR 1.41; 95% CI [1.07\u20131.86]; p = 0.016) for worse 5-year OS. Multivariate Cox analysis confirms a significant association between liver MTV (HR 1.02; 95% CI [1\u20131.04]; p = 0.042) and decrease 1-year OS. In this study, we demonstrate that in RAI-R DTC, 18F-FDG-PET\/CT parameters of the mediastinum, liver and overall tumor burden were prognostic factors of poor 1-year and 5-year OS. Identifying these criteria could allow early therapeutic intervention in order to improve patients\u2019 survival.<\/jats:p>","DOI":"10.3390\/diagnostics12102381","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T01:52:21Z","timestamp":1665193941000},"page":"2381","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Using 18F-FDG-PET\/CT Metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5838-0155","authenticated-orcid":false,"given":"Malanie","family":"Roy","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Henri Becquerel Cancer Center, 76038 Rouen, France"},{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital of Rouen, 76000 Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agathe","family":"Edet-Sanson","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henri Becquerel Cancer Center, 76038 Rouen, France"},{"name":"QuantIF-LITIS (EA[Equipe d\u2019Accueil] 4108), Faculty of Medicine, University of Rouen, 76183 Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolic Diseases, University Hospital of Rouen, 76000 Rouen, France"},{"name":"U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, INSERM, Institute for Research and Innovation in Biomedicine, 76821 Mont-Saint-Aignan, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Vera","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henri Becquerel Cancer Center, 76038 Rouen, France"},{"name":"QuantIF-LITIS (EA[Equipe d\u2019Accueil] 4108), Faculty of Medicine, University of Rouen, 76183 Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-9910","authenticated-orcid":false,"given":"Pierre","family":"Decazes","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Henri Becquerel Cancer Center, 76038 Rouen, France"},{"name":"QuantIF-LITIS (EA[Equipe d\u2019Accueil] 4108), Faculty of Medicine, University of Rouen, 76183 Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","unstructured":"International Agency for Research on Cancer (2021, February 27). Cancer Today, Available online: http:\/\/gco.iarc.fr\/today\/home."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1056\/NEJMra1501993","article-title":"Biologic and Clinical Perspectives on Thyroid Cancer","volume":"375","author":"Fagin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1470-2045(07)70034-7","article-title":"New therapeutic approaches for metastatic thyroid carcinoma","volume":"8","author":"Baudin","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"R209","DOI":"10.1530\/ERC-17-0542","article-title":"Treatment of refractory thyroid cancer","volume":"25","author":"Berdelou","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.ejca.2006.04.026","article-title":"EUROCARE Working Group Variation in relative survival of thyroid cancers in Europe: Results from the analysis on 21 countries over the period 1983\u20131994 (EUROCARE-3 study)","volume":"42","author":"Colonna","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_10","first-page":"2041","article-title":"Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades","volume":"80","author":"Dinneen","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur. Thyroid J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., Greenhalgh, J., Duarte, R., and Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-6369-7"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0014-2964(79)90291-3","article-title":"A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group","volume":"15","author":"Byar","year":"1979","journal-title":"Eur. J. Cancer"},{"key":"ref_16","first-page":"1050","article-title":"Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989","volume":"114","author":"Hay","year":"1993","journal-title":"Surgery"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.surg.2003.12.009","article-title":"AMES prognostic index and extent of thyroidectomy for well-differentiated thyroid cancer in the United States","volume":"136","author":"Haigh","year":"2004","journal-title":"Surgery"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/01.sla.0000250445.92336.2a","article-title":"Staging systems for papillary thyroid carcinoma: A review and comparison","volume":"245","author":"Lang","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/thy.2015.0315","article-title":"An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC\/UICC Staging System for Well-Differentiated Thyroid Cancer","volume":"26","author":"Nixon","year":"2016","journal-title":"Thyroid"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/thy.2010.0355","article-title":"Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy","volume":"21","author":"Miyauchi","year":"2011","journal-title":"Thyroid"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.critrevonc.2013.12.007","article-title":"An update on molecular biology of thyroid cancers","volume":"90","author":"Omur","year":"2014","journal-title":"Crit. Rev. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1210\/jc.2008-0607","article-title":"BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","article-title":"Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning","volume":"91","author":"Robbins","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/ERC-10-0233","article-title":"Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?","volume":"18","author":"Deandreis","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12020-019-01999-6","article-title":"Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma","volume":"66","author":"Zhang","year":"2019","journal-title":"Endocrine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cncr.23515","article-title":"Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma","volume":"113","author":"Rivera","year":"2008","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/RLU.0000000000000780","article-title":"Prognostic Value of 18F-FDG PET\/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers","volume":"40","author":"Schvartz","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_28","first-page":"1107","article-title":"Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer","volume":"85","author":"Wang","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00259-016-3551-x","article-title":"The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer","volume":"44","author":"Terroir","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/thy.2018.0597","article-title":"Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association","volume":"29","author":"Gulec","year":"2019","journal-title":"Thyroid"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"R301","DOI":"10.1530\/ERC-15-0300","article-title":"A new appraisal of iodine refractory thyroid cancer","volume":"22","author":"Vaisman","year":"2015","journal-title":"Endocrine-Related Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1089\/thy.2016.0549","article-title":"Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial","volume":"27","author":"Kiyota","year":"2017","journal-title":"Thyroid"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","unstructured":"R Core Team (2012). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing. Available online: http:\/\/www.R-project.org."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas","volume":"21","author":"Wassermann","year":"2015","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000002193","article-title":"Prognostic Value of FDG-PET\/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","volume":"43","author":"Manohar","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kang, S.Y., Bang, J.-I., Kang, K.W., Lee, H.-Y., and Chung, J.-K. (2019). FDG PET\/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218416"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.12703\/P7-22","article-title":"Treatment of distant metastases from follicular cell-derived thyroid cancer","volume":"7","author":"Schlumberger","year":"2015","journal-title":"F1000Prime Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1089\/thy.2017.0102","article-title":"Updated American Joint Committee on Cancer\/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?","volume":"27","author":"Tuttle","year":"2017","journal-title":"Thyroid"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/SLA.0b013e3181b7faf6","article-title":"Differentiated Thyroid Carcinoma Presenting with Distant Metastasis at Initial Diagnosis: Clinical Outcomes and Prognostic Factors","volume":"251","author":"Lee","year":"2010","journal-title":"Ann. Surg."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jcem.84.11.6115","article-title":"Immediate causes of death in thyroid carcinoma: Clinicopathological analysis of 161 fatal cases","volume":"84","author":"Kitamura","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1590\/2359-3997000000261","article-title":"Deaths related to differentiated thyroid cancer: A rare but real event","volume":"61","author":"Leite","year":"2017","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.4158\/EP171924.OR","article-title":"Long-term Outcomes and Prognostic Factors in Patients with Differentiated Thyroid Cancer and Distant Metastases","volume":"23","author":"Hirsch","year":"2017","journal-title":"Endocr. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/EJE-12-0405","article-title":"Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: Final results of a phase II trial","volume":"167","author":"Schneider","year":"2012","journal-title":"Eur. J. Endocrinol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","article-title":"Cabozantinib As Salvage Therapy for Patients with Tyrosine Kinase Inhibitor\u2013Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial","volume":"35","author":"Cabanillas","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1530\/ERC-11-0068","article-title":"Rare metastases of differentiated thyroid carcinoma: Pictorial review","volume":"18","author":"Song","year":"2011","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/thy.1996.6.607","article-title":"Metastasis to the Liver in Well-Differentiated Carcinoma of the Thyroid","volume":"6","author":"Shah","year":"1996","journal-title":"Thyroid"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.beem.2017.04.014","article-title":"Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer","volume":"31","author":"Tuttle","year":"2017","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/jc.2005-1322","article-title":"Survival and Death Causes in Differentiated Thyroid Carcinoma","volume":"91","author":"Corssmit","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_51","first-page":"1234","article-title":"Survival and causes of death in thyroid cancer: A population-based study of 2479 cases from Norway","volume":"51","author":"Akslen","year":"1991","journal-title":"Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2265.2005.02304.x","article-title":"Differentiated thyroid carcinoma with distant metastases at presentation: Prognostic factors and outcome","volume":"63","author":"Haq","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/1097-0142(19881001)62:7<1381::AID-CNCR2820620724>3.0.CO;2-R","article-title":"Mortality from papillary thyroid carcinoma. A case-control study of 56 lethal cases","volume":"62","author":"Smith","year":"1988","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.17.3682","article-title":"Refractory Thyroid Cancer: A Paradigm Shift in Treatment Is Not Far Off","volume":"26","author":"Pfister","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1210\/jc.2008-1747","article-title":"Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography\/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer","volume":"94","author":"Leboulleux","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gay, S., Raffa, S., di Pietralata, A.D., Bauckneht, M., Vera, L., Miceli, A., Albertelli, M., Morbelli, S., Giusti, M., and Ferone, D. (2022). 2-[18F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020506"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/10\/2381\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:42Z","timestamp":1760143482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/10\/2381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":56,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["diagnostics12102381"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12102381","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}